FSHD is the second most common form of muscular dystrophy after the Duchenne type, and affects around 1 million people worldwide, with no approved treatments. It tends to cause muscle wasting in the face, shoulder blades, and upper arms.
The deal – which includes an upfront payment of $30 million and possible future payments that could drive the total value up to $400 million – will combine miRecule’s RNA expertise with Sanofi’s nanobody technology, bolted on when it acquired Ablynx in a €3.9 billion deal in 2018.
